Alternatives to CYVADIC combination therapy of soft tissue sarcomas

The CYVADIC combination has been the preferred treatment for soft tissue sarcomas for the last 10 years. Other combination therapies are necessary, because the remission rate achieved with CYVADIC is only 30%. Alternative therapies for these tumors are combinations including cis-platinum, ifosfamide...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1986, Vol.18 Suppl 2 (S2), p.S20-S22
Main Authors: Hartlapp, J H, Münch, H J, Illiger, H J, Wolter, H, Jensen, J C
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - administration & dosage
Cyclophosphamide - administration & dosage
Dacarbazine - administration & dosage
Doxorubicin - administration & dosage
Female
Humans
Ifosfamide - administration & dosage
Male
Middle Aged
Sarcoma - drug therapy
Soft Tissue Neoplasms - drug therapy
Vincristine - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CYVADIC combination has been the preferred treatment for soft tissue sarcomas for the last 10 years. Other combination therapies are necessary, because the remission rate achieved with CYVADIC is only 30%. Alternative therapies for these tumors are combinations including cis-platinum, ifosfamide, epipodophyllin, and high-dose methotrexate. Our therapeutic results with combinations of cis-platinum and ifosfamide are comparable to those achieved with CYVADIC. However, the side-effects, such as nausea, vomiting and fatigue, of cis-platinum used in the palliative treatment of these tumors are intolerable for many patients. A combination of adriamycin and ifosfamide, which leads to a higher remission rate of 44% and has lower toxicity than CYVADIC, is giving encouraging results.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00647444